Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: Clin Cancer Res. 2014 Feb 28;20(9):2338–2349. doi: 10.1158/1078-0432.CCR-13-3157

Figure 2. Impact of CD30 expression and Epstein-Barr virus (EBV) infection on overall survival and progression-free survival of diffuse large B-cell lymphoma (DLBCL) patients.

Figure 2

A and B. Compared to patients with EBER− CD30− DLBCL, patients with EBER+ CD30− patients did not have significantly different OS (P=.560) and PFS (P=.343). C and D. Co-expression of EBER and CD30 in DLBCL showed worse OS (P=.014) compared to patients with EBER− CD30− DLBCL. However, PFS was not significantly different (P=.257) between the two groups. E and F. Worse outcome was observed in patients with EBER+ CD30+ DLBCL compared with EBER+ CD30− DLBCL in OS (P=0.042), but not in PFS (P=.145). G and H. Patients with EBER+ CD30+ DLBCL have significantly worse OS and PFS compared to patients with EBER− CD30+ DLBCL (P<.001 and P=.001, respectively).